The result? There are high-value intracellular targets that neither modality can hit. Without being able to reach these ‘undruggable’ intracellular targets, many of the best-validated drivers ...

Press Release Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, today ...

Members of the RBC team listed what they think could be the next biotech takeout targets. Luca Issi believes ... Brian Abrahams highlighted Intra-Cellular Therapies (ITCI) due to its commercial ...

This current average has increased by 7.65% from the previous average price target of $117.67. The analysis of recent analyst actions sheds light on the perception of Intra-Cellular Therapies by ...

Insilico applied its generative chemistry platform for drug discovery, Chemistry42, to the chosen novel intracellular target. The platform uses generative and scoring engines to come up with hit ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

Find the latest Intra-Cellular Therapies Inc. ITCI analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.